Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BioInvent International AB ( (SE:BINV) ) just unveiled an update.
BioInvent International AB has announced promising results from its Phase 1 study of BI-1206 in combination with KEYTRUDA® (pembrolizumab) for solid tumors, showing significant clinical activity including complete and partial responses. The company plans to initiate Phase 2a expansion cohorts to further investigate this combination in patients with advanced non-small cell lung cancer and uveal melanoma, potentially improving treatment outcomes and addressing unmet medical needs in these cancers.
More about BioInvent International AB
BioInvent International AB is a biotech company specializing in the discovery and development of novel and first-in-class antibodies for cancer immunotherapy. The company focuses on enhancing the efficacy of existing cancer treatments through innovative approaches, targeting a broad range of solid tumors and non-Hodgkin’s lymphoma.
Average Trading Volume: 113,424
Current Market Cap: SEK2.51B
See more insights into BINV stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue